Amgen and BioLabs LA Announce Nammi Therapeutics to Receive the Third Amgen Golden Ticket
- Nammi Therapeutics
- Jan 6, 2023
- 1 min read
Amgen and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticker in Southern California. Nammi Therapeutics will receive one year of lab space at Biolabs LA as well as additional facility benefits and connections to Amgen scientific and business leaders.
The Amgen Golden Ticket winner was chosen by a team of Amgen scientific leaders at a virtual pitch event. Five finalists pitched their business plans before Amgen's internal committee that evaluated the strength and novelty of their scientific rationale, subject matter expertise, and business plan viability. View the file below for the full article.
Recent Posts
See AllNammi Therapeutics, Inc., a clinical stage immuno-oncology company with a diverse pipeline created with the Masked-Immunocytokine (MIC)...
Nammi Therapeutics announces a $1M investment commitment by the Myeloma Investment Fund in a $30M Series B financing round prior to the...
Nammi Therapeutics was featured in the Los Angeles Business Journal. The article featured an interview with David Stover, President and...
Commentaires